MedWorm: Alli

[Department of Error] Department of Error

LANCET — Fri, 19 Mar 2010 00:00:00 +0100

Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606–16—In this Article (Nov 7), the proportion of patients with metabolic syndrome in table 1 (p 1608) should have been: 51% for placebo, 42% for liraglutide 1·2 mg, 36% for liraglutide 1·8 mg, 34% for liraglutide 2·4 mg, 41% for liraglutide 3·0 mg, and 38% for orlistat. The second and third sentences of the seventh paragraph in the Results section (p 1611) should have read: “The proportion of patients with metabolic syndrome at week 20 decreased by 64–75% in those treated with liraglutide 2·4 mg and 3·0 mg. The reduction in the placebo group was 35% and in the orlistat group was 21%.” Finally, figure 4A contai...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Stathmin/oncoprotein 18, a microtubule regulatory protein, is required for survival of both normal and cancer cell lines lacking the tumor suppressor, p53.

Cancer Biology and Therapy — Sat, 06 Mar 2010 19:28:05 +0100

Authors: Carney BK, Cassimeris L Stathmin, a microtubule regulatory protein, is overexpressed in many cancers and required for survival of several cancer lines. In a study of breast cancer cell lines, Alli et al. (Oncogene. 26:1003-12) proposed that stathmin is required for survival of cells lacking p53, but this hypothesis was not tested directly. Here we tested their hypothesis by examining cell survival in cells depleted of stathmin, p53 or both proteins. Comparing HCT116 colon cancer cell lines differing in TP53 genotype, stathmin depletion resulted in significant death only in cells lacking p53. As a second experimental system, we compared the effects of stathmin depletion from HeLa cells, which normally lack detectable levels of p53 due to expression of the HPV E6 protein. Stathm...

Phentermine Diet Pills or What? Buying Legally and Safely Online

PRWeb: Medical Pharmaceuticals — Wed, 03 Mar 2010 15:19:07 +0100

Internet pharmacy sites selling weight loss medications around the world are common, and often illegal according to many national regulatory bodies such as the DEA. Where a buyer resides dictates whether obesity medications such as Phentermine, the USA's most popular prescription diet pill, can be purchased legally online and from whom; e.g. unlicensed / non-US based pharmacies are prohibited in America (FDA/DEA). Up to now finding a web site to provide advice and pills such as Adipex, Meridia, Xenical and Phentramin-d legally no matter where the buyer is resident was virtually impossible, hence the launch of phentermine-or-what.com (PRWeb Mar 3, 2010) Read the full story at http://www.prweb.com/releases/2010/03/prweb3664334.htm (Source: PRWeb: Medical Pharmaceuticals)

Vivus's Qnexa Will Become Decision Resources' Clinical Gold Standard In 2013 For The Treatment Of Obesity

Health News from Medical News Today — Wed, 03 Mar 2010 13:00:00 +0100

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus's Qnexa (the phentermine/topiramate combination) will earn Decision Resources' proprietary clinical gold standard in 2013 and through 2018 following its anticipated U.S. approval for the disease in 2011. Qnexa has competitive advantages in efficacy -- it provides nearly double the weight-loss of current anti-obesity drugs -- and improved delivery over the current clinical gold standard, Roche's Xenical/GlaxoSmithKline's OTC Alli... (Source: Health News from Medical News Today)

Preventing Medical Errors: Warning on Counterfeit Alli

Food and Drug Adminstration (FDA): Patient Safety News — Mon, 01 Mar 2010 05:00:00 +0100

FDA is warning the public about a potentially dangerous counterfeit version of the weight-loss drug Alli (orlistat). To date, all the counterfeits seem to have been sold on the internet. The genuine version of Alli, which is approved by FDA for ove... (Source: Food and Drug Adminstration (FDA): Patient Safety News)

Consumers Alerted to Risks Presented by Counterfeit Alli

Clinical Psychiatry News — Mon, 01 Mar 2010 00:00:00 +0100

Counterfeit versions of Alli, the over-the-counter formulation of the lipase inhibitor orlistat, contain sibutramine, another weight loss agent, and could be “potentially harmful” for consumers, the Food and Drug Administration has announced. (Source: Clinical Psychiatry News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Combination Drugs for Treating Obesity

Current Diabetes Reports — Thu, 25 Feb 2010 17:58:50 +0100

This article discusses the history of combination drug therapy for treating obesity, the lessons learned from that experience, and describes the drug combinations now in development. One combination of two standardized dietary herbal supplements that result in clinically significant weight loss is also described. Obesity is poised to enter the era of combination drug therapy, as is now the routine in the treatment of other chronic diseases like hypertension and diabetes. The advent of combination drug therapy for obesity treatment offers hope for increasing the efficacy of obesity pharmacotherapy. Content Type Journal ArticleDOI 10.1007/s11892-010-0096-4Authors Frank L. Greenway, Louisiana State University System Pennington Biomedical Research Center 6400 Perkins Road Baton Rou...

Effect of Non Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia.

Current Vascular Pharmacology — Thu, 25 Feb 2010 00:00:00 +0100

Authors: Florentin M, Tselepis AD, Elisaf MS, Rizos CV, Mikhailidis DP, Liberopoulos EN Small, dense low density lipoprotein (sdLDL) particles are considered an emerging cardiovascular risk factor. Obese patients with mixed dyslipidaemia frequently have elevated sdLDL-C levels. Therefore, agents that favourably modulate the LDL phenotype may be of clinical value in these patients. We review the efficacy of anti-obesity and lipid lowering drugs other than statins on LDL subfractions in patients with mixed dyslipidaemia primarily focusing on those who are overweight/obese. The literature search was based on PubMed listings up to 26 November 2009. In most studies ezetimibe decreases the large and medium LDL subclasses and, to a lesser extent, the sdLDL particles, while it does not substan...

Journal Scan: A Randomized Trial of a Low-Carbohydrate Diet vs Orlistat Plus a Low-Fat Diet for Weight Loss (Arch Intern Med 2010;170:136-145.)

Cardiosource — Wed, 17 Feb 2010 08:36:38 +0100

Overweight or obese outpatients (n = 146) from the Department of Veterans Affairs primary care clinics in Durham, North Carolina, were randomized to either LCKD instruction (initially, (Source: Cardiosource)

A European review of orlistat has concluded that there is insufficient evidence to show that the drug is associated with more serious liver disorders

Reactions — Mon, 15 Feb 2010 14:06:03 +0100

(Source: Reactions)

[Correspondence] Liraglutide for weight loss in obese people

LANCET — Fri, 12 Feb 2010 00:00:00 +0100

Arne Astrup and colleagues report that treatment of obese individuals with liraglutide, an acylated analogue of glucagon-like peptide 1 (GLP-1), results in more weight loss than placebo or the lipase-inhibitor orlistat. (Source: LANCET)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Obesity in adults

Clinical Evidence — Thu, 11 Feb 2010 23:00:00 +0100

New option(s) added for: Diethylpropion New option for which we found one systematic review. The review found less weight loss with diethylpropion compared with phentermine. Data were from one small RCT and effects of diethylpropion in weight loss are unclear. Categorised as Unknown effectiveness. Mazindol New option for which we found no evidence. Categorised as Unknown effectiveness. Bariatric surgery New option for which we found one systematic review. The review identified two RCTs and three cohort studies assessing the effects of various bariatric surgical techniques (gastric banding, gastric bypass, vertical banded gastroplasty, biliopancreatic diversion, and sleeve gastrectomy) in people with morbid obesity. All studies ...

Peptides from purified soybean β-conglycinin inhibit fatty acid synthase by interaction with the thioesterase catalytic domain

FEBS Journal — Tue, 09 Feb 2010 00:00:00 +0100

The objectives of this study were to identify, purify and validate soy FAS inhibitory peptides and to predict their binding modes. Soy peptides were isolated from hydrolysates of purified [beta]-conglycinin by co-immunoprecipitation and identified using LC-MS/MS. Three peptides, KNPQLR, EITPEKNPQLR and RKQEEDEDEEQQRE, inhibited FAS. The biological activity of these peptides was confirmed by their inhibitory activity against purified chicken FAS (IC50 = 79, 27 and 16 [mu]m, respectively) and a high correlation (r = [minus]0.7) with lipid accumulation in 3T3-L1 adipocytes. The FAS inhibitory potency of soy peptides also correlated with their molecular mass, pI value and the number of negatively charged and hydrophilic residues. Molecular modeling predicted that the large FAS inhibitory pepti...

MHRA: Orlistat safety update

NeLM - Patient Safety — Tue, 09 Feb 2010 00:00:00 +0100

Source: MHRA Area: Evidence > Medication Safety The February 2010 issue of Drug Safety Update from the MHRA features an article updating safety issues related to orlistat, which is available in the UK as Xenical® (120mg capsules; POM) and alli® (60mg capsules; P medicine). The article looks at the following: . The results of a European-wide review of safety information for alli®, which led to updates to the product information, bringing it in line with that for Xenical® (oxalate nephropathy, interaction with levothyroxine and antiepileptic drugs, pancreatitis). Pharmacists should be aware of this information so that they can appropriately advise consumers who wish to buy alli® or discuss its use. Information sent to healt...

Warning: Counterfeit Alli

FDA Consumer Updates — Sat, 06 Feb 2010 08:39:00 +0100

FDA warns of counterfeit weight-loss drug Alli 60 mg capsules (120 count refill pack) sold over the Internet. (Source: FDA Consumer Updates)

Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care

Diabetologia — Thu, 04 Feb 2010 18:08:18 +0100

Conclusions/interpretation Screening for pre-diabetes followed by diet and exercise, or metformin treatment is cost-effective and should be considered for incorporation into current practice. The number of dietitians and exercise physiologists needed to deliver such lifestyle change interventions will need to be increased to appropriately support the intervention. Content Type Journal ArticleCategory ArticleDOI 10.1007/s00125-010-1661-8Authors M. Y. Bertram, The University of Queensland Centre for Burden of Disease and Cost-Effectiveness, School of Population Health Herston Rd Herston Queensland 4006 AustraliaS. S. Lim, The University of Washington Centre for Health Metrics and Evaluation Seattle WA USAJ. J. Barendregt, The University of Queensland Centre for Burden o...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Low-Carb Diet May Lead To Similar Benefits As Weight Loss Medication Combined With A Low-Fat Diet

Health News from Medical News Today — Thu, 04 Feb 2010 08:00:00 +0100

A low-carbohydrate diet appears to be associated with substantial weight loss similar to that produced by a combination of the weight-loss drug orlistat and a low-fat diet, but may be more effective in reducing blood pressure. William S. Yancy Jr., M.D., M.H.S., and colleagues at the Department of Veterans Affairs Medical Center and Duke University Medical Center, Durham, N.C., examined body weight, metabolic and adverse effects in obese or overweight outpatients ages 18 to 70 who were randomly assigned to one therapy or the other for 48 weeks... (Source: Health News from Medical News Today)

Low-Carb Diet May Lead To Similar Benefits As Weight Loss Medication Combined With A Low-Fat Diet

Nutrition/Agriculture News From Medical News Today — Thu, 04 Feb 2010 08:00:00 +0100

A low-carbohydrate diet appears to be associated with substantial weight loss similar to that produced by a combination of the weight-loss drug orlistat and a low-fat diet, but may be more effective in reducing blood pressure. William S. Yancy Jr., M.D., M.H.S., and colleagues at the Department of Veterans Affairs Medical Center and Duke University Medical Center, Durham, N.C... (Source: Nutrition/Agriculture News From Medical News Today)

Significant Visceral Fat Loss Seen Within 12 Weeks With Orlistat

Medscape Today Headlines — Wed, 03 Feb 2010 22:05:31 +0100

Magnetic resonance imaging, which accurately measures visceral fat, shows significant visceral fat loss with orlistat 60 mg within 3 months. Medscape Medical News (Source: Medscape Today Headlines)

Low-carb diet better for weight loss and BP reduction than orlistat

MedWire News - Lipidology — Tue, 02 Feb 2010 00:00:00 +0100

Study results show that consuming a low-carbohydrate, ketogenic diet allows overweight individuals to lose a similar amount of weight and to reduce their blood pressure to a greater degree than those taking orlistat and consuming a low-fat diet. (Source: MedWire News - Lipidology)

Low-carb diet better for weight loss and BP reduction than orlistat

MedWire News - Hypertension — Tue, 02 Feb 2010 00:00:00 +0100

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Effectiveness of Weight Management Interventions in Children: A Targeted Systematic Review for the USPSTF

PEDIATRICS — Mon, 01 Feb 2010 16:03:21 +0100

CONCLUSIONS: Over the past several years, research into weight management in obese children and adolescents has improved in quality and quantity. Despite important gaps, available research supports at least short-term benefits of comprehensive medium- to high-intensity behavioral interventions in obese children and adolescents. (Source: PEDIATRICS)

Counterfeit Alli Poses Risks to Consumers, FDA Warns

Family Practice News — Mon, 01 Feb 2010 00:00:00 +0100

Counterfeit versions of Alli, the over-the-counter formulation of the lipase inhibitor orlistat, contain sibutramine another weight loss agent, and could be “potentially harmful” for consumers, the Food and Drug Administration announced last month. (Source: Family Practice News)

Liraglutide Fosters Weight Loss in Obese

Cardiology News — Mon, 01 Feb 2010 00:00:00 +0100

Different doses of liraglutide, a human glucagon-like peptide-1 analogue developed to treat type 2 diabetes, were associated with significantly greater weight loss compared with orlistat and placebo in a European multicenter study of more than 500 obese adults without type 2 diabetes. (Source: Cardiology News)

FDA: Counterfeit Alli Is Hazardous

Cardiology News — Mon, 01 Feb 2010 00:00:00 +0100

A Food and Drug Administration analysis of counterfeit Alli, the over-the-counter formulation of the lipase inhibitor orlistat, has found that the fake product not only contains sibutramine but, when taken at the recommended daily dose, may deliver twice the recommended dose of that drug. (Source: Cardiology News)

Fake Alli Has Dangerous Dose of Sibutramine

Ob.Gyn. News — Mon, 01 Feb 2010 00:00:00 +0100

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Counterfeit Alli Has High Doses of Sibutramine

Clinical Endocrinology News — Mon, 01 Feb 2010 00:00:00 +0100

Lipase inhibitor orlistat decreases incorporation of eicosapentaenoic and docosahexaenoic acids in rat tissues

Nutrition Research — Mon, 01 Feb 2010 00:00:00 +0100

Abstract: Orlistat is a gastric and pancreatic lipases inhibitor that is often prescribed to obese subjects. Orlistat has been shown to decrease the absorption of biologically important lipophilic micronutrients such as liposoluble vitamins. We hypothesized that long-term administration of orlistat may lower the incorporation of n-3 long-chain polyunsaturated fatty acids (LC-PUFA) in blood lipids and tissues. This hypothesis was tested in rats fed a diet supplemented with fish oil as a source of n-3 LC-PUFA. Male Wistar rats (n = 18) were divided into 3 groups and fed experimental high-fat diets containing fish oil (control diet) or fish oil plus orlistat (200 and 400 mg/kg of diet) over the course of 3 weeks. Fat absorption and the level of eicosapentaenoic acid (EPA) and docosahexaenoic ...

In New Data Alli Proven To Reduce Visceral Fat, A Dangerous Fat Linked To Many Life-Threatening Diseases

Health News from Medical News Today — Sat, 30 Jan 2010 08:00:00 +0100

New studies show that overweight and obese people using alli® (orlistat 60 mg) with a reduced calorie, lower-fat diet can significantly reduce weight, visceral fat, and waist circumference and therefore may reduce their risk of type 2 diabetes, hypertension, heart disease and stroke.1,2 The studies were presented at the 1st International Congress on Abdominal Obesity in Hong Kong. alli is the only FDA-approved OTC weight loss aid that is clinically proven to boost weight loss by 50 percent and significantly reduce excess visceral fat... (Source: Health News from Medical News Today)

In New Data Alli Proven To Reduce Visceral Fat, A Dangerous Fat Linked To Many Life-Threatening Diseases

Hypertension News From Medical News Today — Sat, 30 Jan 2010 08:00:00 +0100

New studies show that overweight and obese people using alli® (orlistat 60 mg) with a reduced calorie, lower-fat diet can significantly reduce weight, visceral fat, and waist circumference and therefore may reduce their risk of type 2 diabetes, hypertension, heart disease and stroke.1,2 The studies were presented at the 1st International Congress on Abdominal Obesity in Hong Kong... (Source: Hypertension News From Medical News Today)

Low-carb diet beats drug to lower blood pressure

OnMedica Latest News — Thu, 28 Jan 2010 00:00:00 +0100

Diet is as effective as orlistat in lowering weightRelated items from OnMedicaHigh salt intake strongly linked to stroke and CVDObesity increases health risk for everyoneBooklet cuts antibiotic use for respiratory infectionsMortality rises at low and high blood glucose levelsExercise in middle years brings healthy old age (Source: OnMedica Latest News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Paper round: Thursday

OnMedica Latest News — Thu, 28 Jan 2010 00:00:00 +0100

Botched chlamydia testing schemes, the rise and fall of waistlines, and moreRelated items from OnMedicaMHRA warns public about fake orlistat sold onlineSpineless spinMortality rises at low and high blood glucose levelsDying patients must have access to 24/7 care at end of lifeLow-carb diet beats drug to lower blood pressure (Source: OnMedica Latest News)

Low-carb diets and blood pressure

NHS News Feed — Wed, 27 Jan 2010 11:13:00 +0100

Conclusion This is a generally well-designed study. However, interpretations should be made with care. The study doesn’t provide evidence that the low-carb diet is better than the low-fat/orlistat combination diet. The main outcome that the study was designed to assess was weight change. This was the same between both groups at the end of the study. The press has focused on the finding that the low-carb diet reduced blood pressure to a greater extent. However, although the low-carb diet was associated with improved results for some outcomes, other outcomes were better with the low-fat/orlistat diet. The considerable number of statistical tests that were carried out for other outcomes (that were not the prime focus of this study) reduces the reliability of these results. Although...

Alli proven to reduce visceral fat, a dangerous fat linked to many life-threatening diseases

EurekAlert! - Medicine and Health — Wed, 27 Jan 2010 05:00:00 +0100

(Edelman Public Relations) New studies show that overweight and obese people using alli (orlistat 60 mg) with a reduced calorie, lower-fat diet can significantly reduce weight, visceral fat, and waist circumference and therefore may reduce their risk of type 2 diabetes, hypertension, heart disease and stroke. The studies were presented at the 1st International Congress on Abdominal Obesity in Hong Kong earlier today. (Source: EurekAlert! - Medicine and Health)

MHRA warns of dangers of counterfeit anti-obesity drug alli

HealthcareRepublic Independent Nurse News — Wed, 27 Jan 2010 00:05:00 +0100

The MHRA is warning of the dangers of buying medicines from unregulated websites after the discovery in the US of counterfeit weight-loss drug alli. (Source: HealthcareRepublic Independent Nurse News)

MHRA warns public about fake orlistat sold online

OnMedica Latest News — Wed, 27 Jan 2010 00:00:00 +0100

Counterfeit 'orlistat' contains suspended weight-loss drug sibutramineRelated items from OnMedicaPoor patients more likely to die after heart surgery than richMillions of adults risk buying 'fake' drugs Plan launched to curb 'couch potato culture'Plans launched to curb over-use of antipsychoticsExperts launch public health manifesto (Source: OnMedica Latest News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Low-Carb Ketogenic Diet Gets Better Results Than Diet Pill

Modern Medicine — Wed, 27 Jan 2010 00:00:00 +0100

Adhering to a low-carbohydrate, ketogenic diet produces similar outcomes to the weight-loss drug orlistat and a low fat diet in terms of weight loss, serum lipid profile and blood sugar, but it is more effective at lowering blood pressure, according to a study in the Jan. 25 issue of the Archives of Internal Medicine. (Source: Modern Medicine)

Low Carb Diet Lowered Blood Pressure More Effectively Than Weight Loss Pill

Health News from Medical News Today — Tue, 26 Jan 2010 19:00:00 +0100

A new study from the US showed that two popular weight loss methods, one using the obesity treatment weight-loss pill orlistat plus a low-fat diet and another just based on a low carb diet were equally effective at helping people lose significant amounts of weight, but in a surprising twist found that that the low carb diet was much better at helping them lower blood pressure... (Source: Health News from Medical News Today)

Low Carb Diet Lowered Blood Pressure More Effectively Than Weight Loss Pill

Hypertension News From Medical News Today — Tue, 26 Jan 2010 19:00:00 +0100

Low-carb diet effective at lowering blood pressure

ScienceDaily Headlines — Tue, 26 Jan 2010 16:11:46 +0100

Low-Carb Diet Effective At Lowering Blood Pressure

Health News from Medical News Today — Tue, 26 Jan 2010 12:00:00 +0100

In a head-to-head comparison, two popular weight loss methods proved equally effective at helping participants lose significant amounts of weight. But, in a surprising twist, a low-carbohydrate diet proved better at lowering blood pressure than the weight-loss drug orlistat, according to researchers at Veterans Affairs Medical Center and Duke University Medical Center. The findings send an important message to hypertensive people trying to lose weight, says William S. Yancy, Jr., MD, lead author of the study in the Jan... (Source: Health News from Medical News Today)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Low-Carb Diet Effective At Lowering Blood Pressure

Obesity / Weight Loss / Fitness News From Medical News Today — Tue, 26 Jan 2010 12:00:00 +0100

In a head-to-head comparison, two popular weight loss methods proved equally effective at helping participants lose significant amounts of weight. But, in a surprising twist, a low-carbohydrate diet proved better at lowering blood pressure than the weight-loss drug orlistat, according to researchers at Veterans Affairs Medical Center and Duke University Medical Center... (Source: Obesity / Weight Loss / Fitness News From Medical News Today)

Warning Over Internet Sales Of Counterfeit Weight Loss Medication

IT / Internet / E-mail News From Medical News Today — Tue, 26 Jan 2010 11:00:00 +0100

Warning Over Internet Sales Of Counterfeit Weight Loss Medication

Health News from Medical News Today — Tue, 26 Jan 2010 11:00:00 +0100

The Medicines and Healthcare products Regulatory Agency (MHRA) is warning consumers of the dangers of buying medicines from unregulated websites after the discovery in the United States of counterfeit Alli, a weight loss drug. The Food and Drugs Administration (FDA) in the US has been working with pharmaceutical manufacturer GlaxoSmithKline (GSK) following the report of counterfeit Alli, which although has not been found in the United Kingdom, is still potentially available to UK customers via the internet... (Source: Health News from Medical News Today)

MHRA warning on internet sales of counterfeit weight loss medication

NeLM - News — Tue, 26 Jan 2010 00:00:00 +0100

Source: MHRA Area: News Following the US Food and Drug Administration warning about the availability of counterfeit Alli which contained both orlistat and sibutramine over the internet, the Medicines and Healthcare products Regulatory Agency (MHRA) is warning consumers of the dangers of buying medicines from unregulated websites Although the product has not been found in the United Kingdom, it is still potentially available to UK customers via the internet. The MHRA alert states that the counterfeit Alli can be distinguished from the genuine product by the following means: . the absence of a Lot code on the end flap of the outer packaging . a plain foil inner safety seal under the plastic cap, without any printed words - the authentic product seal is marked...

Low carbohydrate diet similar to orlistat plus low fat diet for weight loss and may reduce BP better

NeLM - News — Tue, 26 Jan 2010 00:00:00 +0100

Source: Arch Internal Med Area: News In obese people, a low carbohydrate ketogenic diet gives similar weight loss and better blood pressure (BP) control than the combination of orlistat and a low fat diet, according to a controlled trial. Low carbohydrate and orlistat plus low fat diets are both effective weight loss therapies, however they have not been compared. This trial aimed to compare the two options, specifically including patients with type 2 diabetes. Participants were recruited from outpatient clinics affiliated to one US Veterans Affairs Medical Centre. They were randomised to low carbohydrate (<20gm daily initially) or low fat (fat <30% of daily calories) plus orlistat 120mg three times daily; both interventions were delivered via small-group sessions e...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

A Randomized Trial of a Low-Carbohydrate Diet vs Orlistat Plus a Low-Fat Diet for Weight Loss [Original Investigation]

Archives of Internal Medicine — Mon, 25 Jan 2010 20:52:05 +0100

Conclusion In a sample of medical outpatients, an LCKD led to similar improvements as O + LFD for weight, serum lipid, and glycemic parameters and was more effective for lowering blood pressure. Trial Registration clinicaltrials.gov Identifier: NCT00108524 (Source: Archives of Internal Medicine)

Nonsurgical Weight Loss for Extreme Obesity in Primary Care Settings: Results of the Louisiana Obese Subjects Study [Original Investigation]

Archives of Internal Medicine — Mon, 25 Jan 2010 20:52:05 +0100

Conclusion Primary care practices can initiate effective medical management for extreme obesity; future efforts must target improving retention and weight loss maintenance. Trial Registration clinicaltrials.gov Identifier: NCT00115063 (Source: Archives of Internal Medicine)

Low-Carb Diet Edges Low Fat Plus Weight-Loss Drug (CME/CE)

MedPage Today Primary Care — Mon, 25 Jan 2010 20:00:00 +0100

Weight loss was the same and blood pressure control was more effective with a low-carbohydrate diet than a low-fat regimen supplemented by the diet drug orlistat (Xenical, Alli), a randomized trial found. (Source: MedPage Today Primary Care)

Feds Find Twice Max Dose of Stimulant in Weight Drug Fake

MedPage Today Product Alert — Mon, 25 Jan 2010 15:34:13 +0100

WASHINGTON (MedPage Today) -- FDA laboratory tests showed counterfeit samples of the weight-loss drug Alli contain twice the maximum recommended dose of sibutramine, the potentially dangerous active ingredient in another diet pill. (Source: MedPage Today Product Alert)

Counterfeit Alli Prompts FDA Warning

About Diabetes — Mon, 25 Jan 2010 00:00:00 +0100

The FDA has issued a warning that counterfeit bottles of Alli, the popular over-the-counter weight loss drug have been found. The counterfeit capsules contain sibutramine, a drug that is also known by the brand name, Meridia, a prescription weight loss drug that is a controlled substance. Alli contains orlistat, a medication that works by blocking the absorption of fat from food. Sibutramine works by triggering the brain to make a person feel full or satisfied while eating less. The counterfeit Alli does not contain orlistat. It contains sibutramine, which can increase blood pressure and heart rate, which can cause serious problems in people with cardiovascular conditions. If you have purchased Alli recently, especially from the internet, be aware that the product may contain sibutramine. ...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Fake Alli diet pills can pose health risks

CNN.com - Health — Sat, 23 Jan 2010 21:02:05 +0100

Counterfeit capsules of the diet drug Alli that are sold online can pose a serious health risk to some users, a research director from the Food and Drug Administration said Saturday. (Source: CNN.com - Health)

Alli 60 mg capsules (120 count refill kit): Counterfeit Product

FDA MedWatch — Sat, 23 Jan 2010 21:00:00 +0100

UPDATE [01/23/2010] Previous alert updated with information on laboratory analysis of sibutramine levels in counterfeit product - Product sold over the internet contains controlled substance sibutramine. (Source: FDA MedWatch)

FDA warns of counterfeit AlliT (orlistat) 60 mg capsules (120 count refill kit) sold online

NeLM - News — Thu, 21 Jan 2010 00:00:00 +0100

Source: FDA Area: News The FDA has notified consumers and healthcare professionals about a counterfeit and potentially harmful version of AlliT (orlistat) 60 mg capsules (120 count refill kit). The counterfeit version contained sibutramine and orlistat. GSK has determined that the counterfeit product has only been sold over the internet at this time. The differences between the counterfeit and authentic products are described in both text and photos in the Agency's press release at the link below. (Source: NeLM - News)

Fake Alli Sold on Internet

Medscape Today Headlines — Wed, 20 Jan 2010 01:09:19 +0100

Fake, "potentially harmful" versions of the weight loss drug Alli are being sold on Internet auction sites such as eBay, the FDA and GlaxoSmithKline warn. WebMD Health News (Source: Medscape Today Headlines)

FDA Warns About Counterfeit Weight Loss Drug Alli

Drugs.com - Pharma News — Tue, 19 Jan 2010 15:25:39 +0100

From Associated Press (January 19, 2010) NEW YORK--The Food and Drug Administration warned consumers Monday about counterfeit and potentially harmful capsules of GlaxoSmithKline’s over-the-counter weight loss drug Alli. The FDA said... (Source: Drugs.com - Pharma News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Drug Safety: OTC Med Recall Expansion, Counterfeit Alli

Physician's First Watch current issue — Tue, 19 Jan 2010 13:04:31 +0100

(Source: Physician's First Watch current issue)

FDA Warns of Fake OTC Weight-Loss Drug

MedPage Today Product Alert — Tue, 19 Jan 2010 12:43:13 +0100

WASHINGTON (MedPage Today) -- The FDA warned patients of a counterfeit version of an over-the-counter weight-loss drug, which replaces the drug's active ingredient orlistat with the potentially harmful sibutramine. (Source: MedPage Today Product Alert)

FDA Warns Consumers about Counterfeit Alli

Drugs.com - Pharma News — Tue, 19 Jan 2010 12:20:32 +0100

The counterfeit products contain controlled substance sibutramine ROCKVILLE, Md., Jan. 18. 2010--The U.S. Food and Drug Administration is today warning consumers about a counterfeit and potentially harmful version of Alli 60 mg capsules (120... (Source: Drugs.com - Pharma News)

FDA Warns Consumers About Counterfeit Alli

Health News from Medical News Today — Tue, 19 Jan 2010 08:00:00 +0100

The U.S. Food and Drug Administration is warning consumers about a counterfeit and potentially harmful version of Alli 60 mg capsules (120 count refill kit). Preliminary laboratory tests conducted by GlaxoSmithKline (GSK)-the maker of the FDA approved over-the-counter weight-loss product- revealed that the counterfeit version did not contain orlistat, the active ingredient in its product. Instead, the counterfeit product contained the controlled substance sibutramine. Sibutramine is a drug that should not be used in certain patient populations or without physician oversight... (Source: Health News from Medical News Today)

FDA Warns Consumers About Counterfeit Alli

Obesity / Weight Loss / Fitness News From Medical News Today — Tue, 19 Jan 2010 08:00:00 +0100

The U.S. Food and Drug Administration is warning consumers about a counterfeit and potentially harmful version of Alli 60 mg capsules (120 count refill kit). Preliminary laboratory tests conducted by GlaxoSmithKline (GSK)-the maker of the FDA approved over-the-counter weight-loss product- revealed that the counterfeit version did not contain orlistat, the active ingredient in its product... (Source: Obesity / Weight Loss / Fitness News From Medical News Today)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

FDA Warns Consumers about Counterfeit Alli

MedlinePlus Health News — Tue, 19 Jan 2010 06:08:25 +0100

Source: Food and Drug Administration Related MedlinePlus Topics: Drug Safety, Over-the-Counter Medicines, Weight Control (Source: MedlinePlus Health News)

Fake Alli Sold on Internet

WebMD Health — Tue, 19 Jan 2010 05:00:00 +0100

Fake, "potentially harmful" versions of the weight loss drug Alli are being sold on Internet auction sites such as eBay, the FDA and GlaxoSmithKline warn. (Source: WebMD Health)

Cochrane review: Long-term effects of weight-reducing drugs in hypertensive patients

NeLM - Drug Class Focused Reviews — Tue, 19 Jan 2010 00:00:00 +0100

Source: Cochrane Library Area: Evidence > Drug Class Focused Reviews Background All major guidelines for antihypertensive therapy recommend weight loss; anti-obesity drugs might be a helpful option. Objectives Primary objectives: To assess the long-term effects of pharmacologically induced reduction in body weight with orlistat, sibutramine or rimonabant on: - all cause mortality - cardiovascular morbidity - adverse events Secondary objectives: - changes in systolic and/or diastolic blood pressure - body weight reduction Search strategy Studies were obtained from computerised searches of Ovid MEDLINE, EMBASE, CENTRAL and from hand searches in reference lists and systematic reviews. Selection criteria Randomized controlled trials in adult hypertens...

FDA Warns of Fake Alli

WSJ.com: Health — Mon, 18 Jan 2010 23:27:11 +0100

The Food and Drug Administration Monday warned consumers about a counterfeit version of GlaxoSmithKline's weight-loss drug Alli purchased by consumers on the Internet. (Source: WSJ.com: Health)

Alli 60 mg capsules (120 count refill kit): Counterfeit Product

FDA MedWatch — Mon, 18 Jan 2010 15:50:00 +0100

Product sold over the internet contains controlled substance sibutramine. (Source: FDA MedWatch)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

FDA Warns Consumers about Counterfeit Alli

Food and Drug Administration — Mon, 18 Jan 2010 14:44:00 +0100

The U.S. Food and Drug Administration is today warning consumers about a counterfeit and potentially harmful version of Alli 60 mg capsules (120 count refill kit). Preliminary laboratory tests conducted by GlaxoSmithKline (GSK)—the maker of the FDA approved over-the-counter weight-loss product— revealed that the counterfeit version did not contain orlistat, the active ingredient in its product. Instead, the counterfeit product contained the controlled substance sibutramine. Sibutramine is a drug that should not be used in certain patient populations or without physician oversight. Sibutramine can also interact in a harmful way with other medications the consumer may be taking. (Source: Food and Drug Administration)

FDA Warns Consumers about Counterfeit Alli

Food and Drug Administration — Mon, 18 Jan 2010 14:23:00 +0100

Acute pancreatitis following orlistat therapy: report of two cases.

JOP — Wed, 13 Jan 2010 19:32:03 +0100

CONCLUSIONS: Our reports suggest orlistat can trigger drug induced acute pancreatitis in certain patients. For patients presenting with abdominal pain soon after commencing orlistat, a diagnosis of pancreatitis must be considered. We also recommend cautious use of orlistat in patients at risk of pancreatic injury. PMID: 20065556 [PubMed - in process] (Source: JOP)

ALLI (Orlistat) Capsule [GlaxoSmithKline Consumer Healthcare LP]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 08 Jan 2010 05:00:00 +0100

Updated Date: Jan 8, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Transgene in pact with Dr Reddy's for obesity drug

The Economic Times Healthcare and Biotech News — Thu, 07 Jan 2010 15:55:49 +0100

Biotechnology firm Transgene Biotek said on Thursday it has signed a pact with Dr Reddy's Lab to manufacture a drug named, Orlistat used in treating obesity. (Source: The Economic Times Healthcare and Biotech News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Transgene in pact with Dr Reddy's for obesity drug

The Economic Times Healthcare and Biotech News — Thu, 07 Jan 2010 15:55:49 +0100

Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction

Journal of Clinical Investigation — Tue, 05 Jan 2010 15:53:09 +0100

The traditional view is that cancer cells predominately produce ATP by glycolysis, rather than by oxidation of energy-providing substrates. Mitochondrial uncoupling — the continuing reduction of oxygen without ATP synthesis — has recently been shown in leukemia cells to circumvent the ability of oxygen to inhibit glycolysis, and may promote the metabolic preference for glycolysis by shifting from pyruvate oxidation to fatty acid oxidation (FAO). Here we have demonstrated that pharmacologic inhibition of FAO with etomoxir or ranolazine inhibited proliferation and sensitized human leukemia cells — cultured alone or on bone marrow stromal cells — to apoptosis induction by ABT-737, a molecule that releases proapoptotic Bcl-2 proteins such as Bak from antiapoptot...

Activity-Based Proteome Profiling of Potential Cellular Targets of Orlistat − An FDA-Approved Drug with Anti-Tumor Activities

Journal of the American Chemical Society — Tue, 22 Dec 2009 14:24:48 +0100

Journal of the American Chemical Society, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Journal of the American Chemical Society)

The Brown University Geriatric Psychopharmacology Update — Wed, 16 Dec 2009 14:16:39 +0100

Conventional Antipsychotics Increase Risk of Death for Patients With DementiaLong-Term Use of Venlafaxine, Nortriptyline Well Tolerated in Elderly Depressed PatientsSertraline-Induced RhabdomyolysisDual Treatment for Comorbid Depression and Chronic Low Back PainIrreversible MAOIs Underutilized in the ElderlyPotential Protective Effects of Orlistat in ADAcetylcholinesterase Inhibitors and Vitamin E Therapy for ADAgitation and Psychosis Induced by Dextromethorphan and Opioid AnalgesicsDraft Guidance on Geriatric Patients in Clinical TrialsUpdated Medication GuidesDrug Safety (Source: The Brown University Geriatric Psychopharmacology Update)

Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis

Obesity Reviews — Wed, 16 Dec 2009 00:00:00 +0100

In conclusion, in the studies using approved sibutramine doses, the drug caused significant elevations in DBP, while the overall SBP effect was near null. Moreover, absence of a blood pressure-lowering effect of orlistat ad a higher DBP elevation by sibutramine were observed for persons with diabetes. Head-to-head studies indicated that an indirect comparison of placebo-adjusted blood pressure effects may overestimate the adverse effects associated with sibutramine, but these studies were small, of shorter duration and of lower quality. (Source: Obesity Reviews)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Cochrane review: Interventions for treating obesity in children

Evidence-Based Child Health: A Cochrane Review Journal — Wed, 16 Dec 2009 00:00:00 +0100

Child and adolescent obesity is increasingly prevalent, and can be associated with significant short- and long-term health consequences.To assess the efficacy of lifestyle, drug and surgical interventions for treating obesity in childhood.We searched CENTRAL on The Cochrane Library Issue 2 2008, MEDLINE, EMBASE, CINAHL, PsycINFO, ISI Web of Science, DARE and NHS EED. Searches were undertaken from 1985 to May 2008. References were checked. No language restrictions were applied.We selected randomised controlled trials (RCTs) of lifestyle (i.e. dietary, physical activity and/or behavioural therapy), drug and surgical interventions for treating obesity in children (mean age under 18 years) with or without the support of family members, with a minimum of six months follow up (three months for a...

Use of psychotropic drugs and analgesics among users of antiobesity drugs - a population based study

Pharmacoepidemiology and Drug Safety — Fri, 11 Dec 2009 00:00:00 +0100

The aim of the present study was to investigate to what extent patients using prescription antiobesity drugs (orlistat, sibutramine and rimonabant) concomitantly or concurrently used psychotropic drugs and analgesics and the association between this drug use and the patients' gender and age. An additional aim was to investigate the sequence of drug therapy among users of both antiobesity drugs and antidepressants or antipsychotics, respectively.Data were retrieved from the Norwegian Prescription Database (NorPD). All patients who had an antiobesity drug (ATC code A08A) dispensed from a Norwegian pharmacy between January 2004 and December 2007 were included in the study.One in four patients using antiobesity drugs had at least on one occasion used a psychotropic drug concomitantly. The most...

Journal Scan: Effects of Liraglutide in the Treatment of Obesity: A Randomised, Double-Blind, Placebo-Controlled Study (Lancet 2009;374:1606-1616.)

Cardiosource — Thu, 03 Dec 2009 00:00:00 +0100

A double-blind, placebo-controlled 20-week trial, with open-label orlistat comparator was conducted in 19 sites in Europe. A total of 564 individuals (18-65 years of age, body mass index 30-40 kg/m2) were randomly assigned, with a telephone or web-based system, to one of four liraglutide doses (1.2 . . . (Source: Cardiosource)

Pharmacotherapy and Surgery Treatment for the Severely Obese Adolescent

Medscape Pharmacist Headlines — Tue, 01 Dec 2009 17:00:00 +0100

Here is a review of treatment with sibutramine or orlistat, current recommendations for bariatric surgical referral, and advice on postsurgical management for patients in this age group. Journal of Pediatric Health Care (Source: Medscape Pharmacist Headlines)

Effects of Orlistat, Alone or Combined with Hypolipidemic Drugs, on Cardiovascular Risk Factors

Medscape Cardiology Headlines — Fri, 20 Nov 2009 17:00:00 +0100

Logically, weight loss with orlistat plus direct lipid lowering from other drugs should add up to enhanced cardiovascular protection. What does the evidence show? Clinical Lipidology (Source: Medscape Cardiology Headlines)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Warning: Counterfeit Alli

FDA Consumer Updates — Wed, 18 Nov 2009 17:06:00 +0100

FDA warns of an unsafe, counterfeit version of the weight-loss drug Alli sold over the Internet. (Source: FDA Consumer Updates)

Nonrandomized Trial of Weight Loss With Orlistat, Nutrition Education, Diet, and Exercise in Obese Patients With CKD: 2-Year Follow-up

American Journal of Kidney Diseases — Wed, 18 Nov 2009 00:00:00 +0100

Conclusions: The weight-management program group showed significant weight loss and weight-loss maintenance in obese patients with CKD and potentially enables obese patients with CKD to undergo kidney transplant. (Source: American Journal of Kidney Diseases)

Viagra: The profitable pill

Guardian Unlimited Science — Mon, 16 Nov 2009 22:43:08 +0100

When Pfizer launched Viagra in 1998 its share price doubled within days. Since then, the little blue pills have become a pillar of profit, earning the company more than £1bn a year.Thanks to promotional campaigns, which included appearances by the footballing legend Pele, male impotence lost some of its stigma and 25 million men requested the pills. In England alone, GPs write about 6m Viagra prescriptions a year.The drug started life in a lab in Sandwich, Kent, where it was developed to treat high blood pressure. Its transformation into a blockbuster treatment for impotence began when volunteers in a clinical trial reported a suspicious number of erections. The overnight success of Viagra prompted Pfizer to wonder if the drug had any effect in women. They raised awareness of a condition ...

Liraglutide Fosters Weight Loss in Nondiabetics

Family Practice News — Sun, 15 Nov 2009 00:00:00 +0100

Different doses of liraglutide, an investigational human glucagon-like peptide-1 analogue developed to treat type 2 diabetes, were associated with significantly greater weight loss when compared with orlistat and placebo in a European multicenter study of over 500 obese adults who did not have type 2 diabetes. (Source: Family Practice News)

Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With Dyslipidemia

Journal of Cardiovascular Pharmacology and Therapeutics — Wed, 11 Nov 2009 02:11:41 +0100

Conclusion: For similar body weight reduction, the combination of ezetimibe with orlistat may be more efficient in LDL-C lowering, whereas the combination of ezetimibe with rimonabant may be more potent in terms of improving HDL-C and triglycerides. (Source: Journal of Cardiovascular Pharmacology and Therapeutics)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Misused Weight-Loss Drug

About.com Eating Disorders — Mon, 09 Nov 2009 00:00:00 +0100

So you create a weight-loss drug, Alli, and put it in an environment in which it's supposed to be given to people who are overweight...and then it ends up in the hands of people who aren't overweight. It's not a case of people getting the stuff on some kind of black market. It's people buying it over the counter in Ireland. According to licensing conditions, pharmacists in Ireland can't sell Alli to anyone who's of normal weight or underweight. But eight out of 20 pharmacies sold the drug to a researcher who is well under the "overweight" threshold. Not a good situation. But I wonder: How is a customer supposed to verify that his or her body mass index is in the proper range to be given the drug without a prescription? Must there be a scale in each pharmacy? I can't imagine a good system...

[Comment] Gastrointestinal hormones and weight management

LANCET — Fri, 06 Nov 2009 00:00:00 +0100

The gastrointestinal tract produces several peptide hormones that participate in regulation of food intake. Some, such as cholecystokinin, glucagon-like peptide-1 (GLP-1), polypeptide YY(3–36), and oxyntomodulin, decrease food intake, and at least one, ghrelin, increases food intake. Such effects indicate that agonists and antagonists to these hormones would make interesting targets for drug treatment of obesity. In The Lancet today, Arne Astrup and colleagues report on use of the GLP-1 agonist liraglutide as a treatment for obesity, by comparison with orlistat, an approved treatment that blocks intestinal lipase, and placebo. Liraglutide is 97% identical to GLP-1 in aminoacid sequence, yet its circulating half-life is extended from 1–2 min to 13 h. (Source: LANCET)

Fears emerge over weight-loss drug's links with kidney damage

The Irish Times - Health — Tue, 03 Nov 2009 09:05:17 +0100

THE EUROPEAN Medicines Agency has recommended the product information for the widely used weight-loss drug Alli be updated after kidney and pancreatic problems were reported in a number of patients using the drug. (Source: The Irish Times - Health)

DTB reviews place of OTC orlistat in the management of obesity

NeLM - Drug Specific Reviews — Tue, 03 Nov 2009 00:00:00 +0100

Source: Drug and Therapeutics Bulletin Area: Evidence > Drug Specific Reviews The November 2009 issue of the Drug and Therapeutics Bulletin (DTB) features a review of OTC orlistat (alli®), which is available in the UK for purchase from pharmacies by adults who are overweight or obese (BMI ?28kg/m2), at a cost of around £55 per month (for up to 6 months). The review covers how it is being sold, practice guidance/training for pharmacists, efficacy data, unwanted effects and its cautions and contra-indications. The authors conclude that OTC orlistat 'provides a reasonable choice for motivated individuals who can afford it'. They note that those who choose to buy it should receive full counselling about gastrointestinal side effects and how these relate to diet. ...

CHMP recommends updating OTC orlistat (alli®) product information

NeLM - News — Mon, 02 Nov 2009 00:00:00 +0100

Source: EMEA Area: News Following assessment of information related to levothyroxine, antiepileptics interactions and adverse events related to pancreatitis and oxalate nephropathy associated with OTC orlistat (alli®), the CHMP recommended updating the product information to reflect that patients taking medicines such as levothyroxine and antiepileptic drugs or patients with kidney disease should consult a doctor before starting treatment and that oxalate nephropathy and pancreatitis have been reported in a number of patients taking this medicine. The CHMP and Glaxo Group Ltd have agreed on a Direct Healthcare Professional Communication concerning this updated information. (Source: NeLM - News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Crystal-Induced Kidney Disease in 2 Kidney Transplant Recipients

American Journal of Kidney Diseases — Mon, 02 Nov 2009 00:00:00 +0100

We report 2 cases of crystal-induced kidney disease in transplant recipients that resulted in kidney failure. (Source: American Journal of Kidney Diseases)

Nondiabetic Patients Lost Weight With Liraglutide

Clinical Endocrinology News — Sun, 01 Nov 2009 00:00:00 +0100

Swine flu vaccine shots eliminate wrinkles, bad breath and varicose veins, too (opinion)

NaturalNews.com — Fri, 30 Oct 2009 07:00:00 +0100

(NaturalNews) The propaganda push for flu vaccines has reached a level of absurdity that's just begging to be made fun of. Today, a flu vaccine story appearing in Reuters claimed that injecting pregnant women with flu shots would increase the birth weight of their babies by half a pound. That same story claimed flu shots are so healthy for pregnant women that they also prevent premature births.It even quotes a team of experts who claim that injecting an expectant mother with a flu shot would reduce the hospitalization of her infants, explaining: "Flu vaccine given to women during pregnancy is 85 percent effective in preventing hospitalization in their infants under 6 months of age."This conclusion was derived from a study of pregnant women in Bangladesh, by the way, and it didn't even use ...

The C type natriuretic peptide receptor tethers AHNAK1 at the plasma membrane to potentiate arachidonic acid-induced calcium mobilization

AJP: Cell Physiology — Thu, 29 Oct 2009 00:34:45 +0100

Arachidonic acid (AA) liberated from membrane phospholipids is known to activate phospholipase C 1 (PLC1) concurrently with AHNAK in nonneuronal cells. The recruitment of AHNAK from the nucleus is required for it to activate PLC1 at the plasma membrane. Here, we identify the C-type natriuretic peptide receptor (NPR-C), an atypical G protein-coupled receptor, as a protein binding partner for AHNAK1 in various cell types. Mass spectrometry and MASCOT analysis of excised bands from NPR-C immunoprecipitation studies revealed multiple signature peptides corresponding to AHNAK1. Glutathione S-transferase (GST) pulldown assays using GST- AHNAK1 fusion proteins corresponding to each of the distinct domains of AHNAK1 showed the C1 domain of AHNAK1 associates with NPR-C. The role of NPR-C in mediati...

Diabetes drug liraglutide 'better than orlistat and placebo for weight loss'

Pulse — Mon, 26 Oct 2009 17:39:00 +0100

A daily injection with liraglutide – the latest incretin drug for diabetes - is better at promoting weight loss than orlistat and placebo, alongside diet and exercise, a new study has found. (Source: Pulse)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Orlistat

Practical Diabetes International — Mon, 26 Oct 2009 00:00:00 +0100

No Abstract. (Source: Practical Diabetes International)

Liraglutide Reduces Weight And Risk Factors In Obese People Without Diabetes (Online First)

Health News from Medical News Today — Sun, 25 Oct 2009 07:00:00 +0100

Liraglutide reduces weight and the prevalence of risk factors in obese people without diabetes. Furthermore, high doses of liraglutide cause greater weight loss than orlistat. These are the conclusions of an Article published Online First (http://www.thelancet. (Source: Health News from Medical News Today)

Health News of the Day

Clinical Cases and Images — Sat, 24 Oct 2009 11:38:00 +0100

is a daily summary made from the selected links I post on Twitter. It is in a bullet points format with links to the original sources which include 350 RSS feeds that produce about 2,500 items per day:Meta-analysis finds 6-13% increased risk of diabetes in those who received statin therapy http://bit.ly/3iX7vd -- Although statin therapy greatly lowers vascular risk, relationship of statins to incident diabetes remains uncertain http://bit.ly/3BFQv5 -- "Statin-Induced Diabetes" - the headline of this editorial may be a bit premature considering the available evidence http://bit.ly/15L33KDiabetes drug liraglutide contains a satiety hormone that helps decrease appetite, it also lowers blood pressure. Liraglutide helps obese adults (without diabetes) lose more weight than the weight-loss drug...

Diabetes drug helps obese adults loss weight

Reuters: Health — Fri, 23 Oct 2009 18:30:59 +0100

NEW YORK (Reuters Health) - Obese adults may shed more weight with the diabetes drug liraglutide than with the weight-loss drug orlistat (Xenical, Alli), suggests a study in The Lancet this week. (Source: Reuters: Health)

Diabetes injection more effective that orlistat for weight loss

Nursing Times Breaking News — Fri, 23 Oct 2009 12:44:00 +0100

Medical trials have revealed a diabetes injection, tested at 19 different hospitals, appears to help weight loss more than leading anti-obesity druh orlistat. (Source: Nursing Times Breaking News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Diabetes injection more effective than orlistat for weight loss

Nursing Times Breaking News — Fri, 23 Oct 2009 12:44:00 +0100

Medical trials have revealed a diabetes injection, tested at 19 different hospitals, appears to help weight loss more than leading anti-obesity druh orlistat. (Source: Nursing Times Breaking News)

Diabetes drug 'trumps fat pill' (BBC News online, 23 October 2009)

Society for Endocrinology — Fri, 23 Oct 2009 12:00:00 +0100

A study published in the Lancet shows that patients treated with the diabetes drug liraglutide were significantly more likely to lose weight than those taking orlistat, a leading obesity drug. Full article (Source: Society for Endocrinology)

Weight loss pills vs anti-fat jab

NHS News Feed — Fri, 23 Oct 2009 11:02:00 +0100

“Patients given a new anti-obesity drug lost more than a stone in weight in five months,” said The Times. The injectable drug, liraglutide, was reported as being almost twice as effective as other treatments in the study. The Daily Mail wrongly reports that the drug has been licensed for use in obese patients in the UK since July. In this high-quality randomised trial, 564 obese or severely obese patients were injected with either 1.2mg to 3.0mg of liraglutide a day, a daily 'dummy' jab, or orlistat pills three times a day. All patients followed a calorie-restricted diet and increased their physical activity. Contrary to some newspaper reports, this drug in is only licensed to treat type 2 diabetes in tablet form in Europe, and is not yet licensed in the US. Average weight loss on the...

Obese People Without Diabetes: Liraglutide Reduces Weight And Prevalence Of Risk Factors

Health News from Medical News Today — Fri, 23 Oct 2009 07:00:00 +0100

An article published Online First and in a future edition of The Lancet reports that liraglutide reduces weight and the prevalence of risk factors in obese people without diabetes. In addition, high doses of liraglutide cause greater weight loss than orlistat. The article is the work of Professor Arne Astrup, Department of Human Nutrition, University of Copenhagen, Denmark, and colleagues. (Source: Health News from Medical News Today)

Journal Scan: Effects of Liraglutide in the Treatment of Obesity: A Randomised, Double-Blind, Placebo-Controlled Study (Lancet 2009;Oct 23:[Epub ahead of print].)

Cardiosource — Fri, 23 Oct 2009 00:00:00 +0100

A double-blind, placebo-controlled, 20-week trial was conducted with an open-label orlistat comparator in 19 sites in Europe. A total of 564 individuals (18-65 years of age, body mass index 30-40 kg/m2) were randomly assigned, with a telephone or web-based system, to one of four liraglutide doses (1. . . (Source: Cardiosource)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

RCT: Liraglutide in the treatment of obesity

NeLM - News — Thu, 22 Oct 2009 23:00:00 +0100

This study was then followed by an 84-week open-label extension. According to the intention to treat analysis: . The liraglutide group lost statistically significantly more weight than the ... (Source: NeLM - News)

GLP-1 analog liraglutide promising in obesity

theHeart.org — Thu, 22 Oct 2009 22:30:00 +0100

A drug originally developed to treat diabetes may have promise as an obesity therapy, a new study shows. Those taking liraglutide, a GLP-1 analog, lost more weight than those on an established obesity medication, orlistat. (Source: theHeart.org)

GLP-1 Analog Liraglutide Promising in Obesity

Medscape Medical News Headlines — Thu, 22 Oct 2009 10:32:00 +0100

Optical urethrotomy under local anaesthesia is a feasible option in urethral stricture disease.

Tropical Doctor — Thu, 22 Oct 2009 00:00:00 +0100

Authors: Munks DG, Alli MO, Goad EH The aim of our study was to assess the feasibility of performing optical urethrotomy for urethral stricture disease under local anaesthesia. A total of 33 patients with radiologically proven urethral stricture underwent optical urethrotomy by a single operator under local anaesthesia. Of these patients, 23 (70%) had stricture involving the corpora spongiosum and 18 (55%) of the patients were dependent on supra-pubic catheters. The procedure was successful in 30 cases (91%). The procedure was very well tolerated (average visual analogue pain score of 2/10) with an extremely low complication rate. The large number of patients with urethral stricture disease and the premium on operating time on formal theatre slates encouraged us to perform these proced...

Patient Characteristics in Behcet Disease: A Retrospective Analysis of 213 Turkish Patients during 20014

American Journal of Clinical Dermatology — Fri, 16 Oct 2009 13:00:23 +0100

(Source: American Journal of Clinical Dermatology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Role of Fat Hydrolysis in Regulating Glucagon-Like Peptide-1 Secretion.

The Journal of Clinical Endocrinology and Metabolism — Thu, 15 Oct 2009 23:00:00 +0100

Conclusion: Generation of long-chain fatty acids through hydrolysis of fat is a critical step for fat-induced stimulation of GLP-1 in humans; the signal is mediated via CCK release and CCK-1 receptors. PMID: 19837920 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

What extent of weight loss can benefit the health-related quality of life in motivated obese Chinese?

Asia Pacific Journal of Clinical Nutrition — Fri, 02 Oct 2009 03:30:04 +0100

Conclusions: The extent, not the type of intervention, of weight loss is highly correlated with the favorable changes in HRQOL at 6-months. Weight loss above 5% of baseline values is necessary to show significant improvements in HRQOL in motivated obese Chinese. PMID: 19786391 [PubMed - in process] (Source: Asia Pacific Journal of Clinical Nutrition)

What are the risks and the benefits of current and emerging weight-loss medications?

Current Diabetes Reports — Tue, 29 Sep 2009 04:11:04 +0100

This article discusses the perceived benefits and risks of these approved medications along with emerging drugs that have shown weight-loss effects. Content Type Journal ArticleDOI 10.1007/s11892-009-0058-xAuthors Jamie R. RobinsonKevin D. Niswender, Vanderbilt University Medical Center Department of Medicine, Molecular Physiology and Biophysics 7435G MRB IV Nashville TN 37232 USA Journal Current Diabetes ReportsOnline ISSN 1539-0829Print ISSN 1534-4827 Journal Volume Volume 9 Journal Issue Volume 9, Number 5 / October, 2009 (Source: Current Diabetes Reports)

Regimen promotes orlistat efficacy in teens

Pearls — Thu, 24 Sep 2009 22:03:00 +0100

Kim J. Masters, MD (Source: Pearls)

FDA Issues Early Communication About Ongoing Safety Review of Weight Loss Drug Orlistat

Gastroenterology — Tue, 22 Sep 2009 00:00:00 +0100

The US Food and Drug Administration (FDA) announced that it is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat. Orlistat is marketed in the United States as a prescription product, Xenical, and as an over-the-counter (OTC) product, Alli. (Source: Gastroenterology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

An orlistat “overdose” in a child

Irish Journal of Medical Science — Thu, 17 Sep 2009 23:28:40 +0100

Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s11845-009-0429-yAuthors M. B. O’Connor, Mallow General Hospital Department of Medicine Mallow Ireland Journal Irish Journal of Medical ScienceOnline ISSN 1863-4362Print ISSN 0021-1265 (Source: Irish Journal of Medical Science)

News from the FDA

Family Practice News — Mon, 14 Sep 2009 23:00:00 +0100

Reports of liver injury, including liver failure, in people taking OTC and prescription orlistat for weight loss are being investigated by the Food and Drug Administration, the agency announced. (Source: Family Practice News)

FDA issues early communication about ongoing safety review of orlistat

Modern Medicine — Sun, 13 Sep 2009 23:00:00 +0100

FDA is reviewing reports of liver injury in patients treated with orlistat (prescription drug, Xenical; OTC drug, Alli) for obesity management or weight loss. (Source: Modern Medicine)

Mapping 3-Dimensional Neovessel Organization Steps Using Micro-Computed Tomography in a Murine Model of Hindlimb Ischemia.

Arteriosclerosis, Thrombosis and Vascular Biology — Wed, 09 Sep 2009 23:00:00 +0100

CONCLUSIONS: This study demonstrated that optimized mCT is a robust method for providing new insights into the 3D understanding of postischemic vessel formation. PMID: 19745199 [PubMed - as supplied by publisher] (Source: Arteriosclerosis, Thrombosis and Vascular Biology)

FDA Reviewing Safety Profile of Popular Weight Loss Products

AAFP Health of the Public — Wed, 09 Sep 2009 20:30:00 +0100

Another weight loss drug has come under FDA scrutiny. The agency said Aug. 24 that it is reviewing the safety of orlistat after receiving reports of liver injury in patients using the drug, which is marketed as the prescription drug Xenical and the OTC medication Alli. (Source: AAFP Health of the Public)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

More children taking obesity drugs

NHS News Feed — Thu, 03 Sep 2009 11:27:00 +0100

“The number of children on anti-obesity drugs has risen 15-fold in the last 10 years”, The Daily Telegraph reported. It said that a study of data from GPs between 1999 and 2006 shows up to 1,300 children and teenagers a year could be prescribed the drugs, even though they are not licensed for use by children. The newspaper said that most prescriptions “were for 14-year-olds, although 25 prescriptions were written for children under the age of 12”. This research looked at a selection of GP records from practices covering 5% of the population. It is a well-conducted study and the results are likely to be representative of the rest of the UK. It found that the prescribing of unlicensed anti-obesity drugs to children and adolescents has increased significantly in the past eight y...

Rise in anti-obesity drug prescribing for children and adolescents in the UK

NeLM - News — Wed, 02 Sep 2009 23:00:00 +0100

Source: British Journal of Clinical Pharmacology Area: News According to a report in the British Journal of Clinical Pharmacology, the number of young people receiving prescriptions for anti-obesity drugs has increased 15-fold since 1999, but most stop using them before they could expect to see any benefit. These findings come from a population-based study investigating the use of unlicensed anti-obesity drugs (orlistat, sibutramine and rimonabant) in children and adolescents (0-18 years) in the UK using prescribing data (January 1999 and 31 December 2006) from the UK General Practice Research database. The following findings were reported for the 452 subjects who received 1334 prescriptions during the study period: . The annual prevalence of anti-obe...

Effects of obesity reduction on cardiovascular risk factors: comparison of individual and group treatment--substudy of the Croatian Healthy Weight Loss Programme.

Collegium Antropologicum — Tue, 01 Sep 2009 00:00:00 +0100

Authors: Jovanović Z, Crncević-Orlić Z, Stimac D, Kokić S, Persić V, Ruzić T, Goll-Barić S Prevention of obesity may help reduce the morbidity and mortality from cardiovascular diseases. In Croatia, over half of adult population is overweight. Aldo the basic medical principles of healthy weight-loss programmes are well known, it is believed that mainly because of the leak of successful therapeutic approach obesity remains the most challenging changeable cardiovascular risk factor in nowadays clinical practice. Objective of this Croatian Healthy Weight Loss Programme substudy was to determine effects and differences between the intensive group and intensive individual weight-loss program on weight loss and cardiovascular risk factor. A clinical ...

FDA Reviewing Liver Safety of Weight Loss Drug

Clinical Endocrinology News — Mon, 31 Aug 2009 23:00:00 +0100

Reports of liver injury, including liver failure, in people taking over-the-counter and prescription orlistat for weight loss are being investigated by the Food and Drug Administration. (Source: Clinical Endocrinology News)

Comparing clinician knowledge and online information regarding Alli (Orlistat)

International Journal of Medical Informatics — Mon, 31 Aug 2009 23:00:00 +0100

Conclusions: Forum answers were comparable to clinicians’ answers with respect to accuracy and completeness, but answers from both sources were unsatisfactory. (Source: International Journal of Medical Informatics)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

US FDA reviewing safety of orlistat

Reactions — Mon, 31 Aug 2009 12:03:34 +0100

(Source: Reactions)

Concerns About Anti-Obesity Drug Orlistat

Health News from Medical News Today — Mon, 31 Aug 2009 07:00:00 +0100

US authorities are investigating concerns that anti-obesity drug Orlistat may cause liver damage. Orlistat went on sale under the brand name Alli without the need for a prescription in the UK in April. The US Food and Drug Administration (FDA) has received more than 30 reports linking the drug to serious liver injury. (Source: Health News from Medical News Today)

Medications for Obesity: Mechanisms and Applications

Clinics in Chest Medicine — Thu, 27 Aug 2009 12:52:12 +0100

Medications can significantly increase weight loss compared with placebo in most trials. In general, patients can expect a weight loss of 8% to 10% from baseline provided they adhere to the weight-loss program and take medications regularly. All medications have side effects that need to be considered before initiating treatment, however. For sibutramine, there is an increase in blood pressure and heart rate that may require discontinuation of the drug in a small percentage of patients. For orlistat, the principal side effect is gastrointestinal in origin resulting from the increased activity of the lower bowel. Cannabinoid receptor antagonists, once a promising target, are no longer under study. Other medications are in clinical trials and on their way. (Source: Clinics in Chest Medicine)

FDA Reviewing Reports Linking Weight Loss Drug To Liver Injuries

Health News from Medical News Today — Thu, 27 Aug 2009 08:00:00 +0100

The US Food and Drug Administration (FDA) announced this week that it is reviewing reports of liver injury in people who took the weight loss drug orlistat, which is marketed as the prescription drug Xenical and over the counter (OTC) as Alli. However, the federal agency said in the meantime consumers should continue to use the product as prescribed or directed. (Source: Health News from Medical News Today)

GlaxoSmithKline Statement Confirming alli Safety

Drugs.com - Pharma News — Wed, 26 Aug 2009 13:16:51 +0100

PITTSBURGH, Aug. 25 /PRNewswire/ -- The following is the GlaxoSmithKline statement in response to the FDA's Early Communication about the safety review of orlistat: "GSK stands firmly behind the safety and efficacy of alli. Our primary priority... (Source: Drugs.com - Pharma News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Obesity drug fears investigated (BBC news online, 25 August 2009)

Society for Endocrinology — Wed, 26 Aug 2009 12:00:00 +0100

The anti-obesity drug Orlistat has been linked with liver damage. The US Food and Drug Administration are now reviewing the safety of the drug, which works by blocking fat absorption in the body. Full article (Source: Society for Endocrinology)

Weightloss pill may damage liver

Guardian Unlimited Science — Tue, 25 Aug 2009 23:19:21 +0100

A slimming drug available over the counter in the UK is being investigated for links to 32 cases of liver damage by the US Food and Drug Administration.The FDA began investigating orlistat, sold over the counter as Alli, and its potential links to liver damage earlier this year after concerns were raised about potentially harmful side effects. On Monday, the agency said it was assessing 32 reports of serious liver injury in patients, 27 of whom were hospitalised.Alli works by absorbing about a quarter of the fat from food and preventing it from being retained as extra weight. It went on sale in the UK in April and is available to dieters without a prescription. About 200,000 people in the UK have purchased the drug. Tablets are available to adults deemed to be overweight – with a body ma...

Diet Drug Orlistat may be Associated with Liver Damage

About Diabetes — Tue, 25 Aug 2009 23:00:00 +0100

The weight loss drug orlistat, has been flagged by the FDA as a drug that bears watching. Orlistat is the generic name for the prescription drug Xenical and the over-the-counter... (Source: About Diabetes)

The C type natriuretic peptide receptor tethers AHNAK1 at the plasma membrane to potentiate arachidonic acid induced calcium mobilization.

American Journal of Physiology. Cell Physiology — Tue, 25 Aug 2009 23:00:00 +0100

Authors: Alli AA, Gower WR Arachidonic acid (AA) liberated from membrane phospholipids is known to activate phospholipase C gamma1 (PLCgamma1) concurrently with AHNAK in non-neuronal cells. The recruitment of AHNAK from the nucleus is required for it to activate PLCgamma1 at the plasma membrane. Here, we identify an atypical G protein coupled receptor, the C type natriuretic peptide receptor (NPR-C), as a protein binding partner for AHNAK1 in various cell types. Mass spectrometry and MASCOT analysis of excised bands from NPR-C immunoprecipitation studies revealed multiple signature peptides corresponding to AHNAK1. GST pulldown assays using GST-AHNAK1 fusion proteins corresponding to each of the distinct domains of AHNAK1, showed the C1 domain of AHNAK1 associates with NPR-C. The role ...

FDA safety review of liver-related adverse events with orlistat (AlliT and XenicalT)

NeLM - Nutrition and Metabolism — Tue, 25 Aug 2009 23:00:00 +0100

Source: FDA Area: News The US FDA is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat (POM XenicalTand OTC AlliT). According to the FDA's Adverse Event Reporting System, 32 reports of serious liver injury, including 6 cases of liver failure, were submitted between 1999 and October 2008 in patients using orlistat; 30 of these reports occurred outside the US and 27 cases resulted in hospitalisation. The most commonly reported adverse events were jaundice, weakness and abdominal pain. In addition to the 32 reported cases, the FDA is reviewing other data on suspected cases of liver injury submitted by the manufacturers of orlistat and will communicate its findings once its review is complete. For th...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

FDA to Investigate Liver-Related Adverse Events Seen With Orlistat

Medscape Medical News Headlines — Tue, 25 Aug 2009 16:09:03 +0100

The FDA has warned healthcare professionals about the potential for liver-related adverse events with the weight-loss drug orlistat. Medscape Medical News (Source: Medscape Medical News Headlines)

MedWatch - Orlistat (marketed as Alli and Xenical): FDA reviewing reports of serious liver injury, including liver failure

Drugs.com - Pharma News — Tue, 25 Aug 2009 14:55:26 +0100

ROCKVILLE, Md., Aug. 24, 2009--FDA notified healthcare professionals and patients that it is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat. Orlistat is marketed in the United... (Source: Drugs.com - Pharma News)

US liver safety probe for OTC weight loss drug

Pulse Today Clinical Updates — Tue, 25 Aug 2009 14:50:00 +0100

Regulatory authorities in the United States have ordered a review of the safety of orlistat after reports of serious liver injury in patients taking the drug. (Source: Pulse Today Clinical Updates)

FDA probes safety of over-the-counter weight-loss pill

CTV Health — Tue, 25 Aug 2009 14:43:46 +0100

The Food and Drug Administration is investigating reports of liver damage in patients taking alli, the only non-prescription weight loss drug approved by the agency for sale in the United States. (Source: CTV Health)

Video: Alli Weight Loss Warning

Health News: CBSNews.com — Tue, 25 Aug 2009 13:47:08 +0100

Reports of liver damage when using the over-the-counter weight loss pill Alli are under investigation. Dr. Holly Phillips explains to Maggie Rodriguez. (Source: Health News: CBSNews.com)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

FDA looking into liver problems with GlaxoSmithKline weight-loss drug Alli

bizjournals.com Health Care:Hospitals headlines — Tue, 25 Aug 2009 13:27:22 +0100

The U.S. Food and Drug Administration is taking a closer look at weight-loss drug orlistat, which is marketed over the counter under the name Alli by GlaxoSmithKline. (GSK) (Source: bizjournals.com Health Care:Hospitals headlines)

FDA looking into liver problems with GlaxoSmithKline weight-loss drug Alli

bizjournals.com Health Care:Industry Regulation headlines — Tue, 25 Aug 2009 13:27:22 +0100

The U.S. Food and Drug Administration is taking a closer look at the weight-loss drug orlistat, which is marketed over the counter under the name Alli by GlaxoSmithKline. (GSK) (Source: bizjournals.com Health Care:Industry Regulation headlines)

FDA looking into liver problems with GlaxoSmithKline weight-loss drug Alli

bizjournals.com Health Care:Physician Practices headlines — Tue, 25 Aug 2009 13:27:22 +0100

FDA looking into liver problems with GlaxoSmithKline weight-loss drug Alli

bizjournals.com Health Care:Health Insurance headlines — Tue, 25 Aug 2009 13:27:22 +0100

FDA looking into liver problems with GlaxoSmithKline weight-loss drug Alli

bizjournals.com Health Care:Pharmaceuticals headlines — Tue, 25 Aug 2009 13:27:22 +0100

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

FDA looking into liver problems with GlaxoSmithKline weight-loss drug Alli

bizjournals.com Health Care:Biotechnology headlines — Tue, 25 Aug 2009 13:27:22 +0100

Is Alli Your Liver's Worst Enemy?

ABC News: Health — Tue, 25 Aug 2009 12:40:47 +0100

Reports of liver damage may be connected to the diet pill Alli. (Source: ABC News: Health)

Approved alli linked to liver damage

Pharmacy Europe — Tue, 25 Aug 2009 12:04:35 +0100

Investigations have begun into the only non-prescription weight-loss drug approved by the FDA after reports it causes liver damage (Source: Pharmacy Europe)

FDA Issues Early Communication about Ongoing Safety Review of Weight Loss Drug Orlistat

Drugs.com - Pharma News — Tue, 25 Aug 2009 11:57:45 +0100

Review includes both prescription drug Xenical and OTC drug Alli ROCKVILLE, Md., Aug. 24, 2009--The U.S. Food and Drug Administration announced today that it is reviewing adverse event reports of liver injury in patients taking the weight loss... (Source: Drugs.com - Pharma News)

MedWorm: Alli

[Department of Error] Department of Error

Stathmin/oncoprotein 18, a microtubule regulatory protein, is required for survival of both normal and cancer cell lines lacking the tumor suppressor, p53.

Phentermine Diet Pills or What? Buying Legally and Safely Online

Vivus's Qnexa Will Become Decision Resources' Clinical Gold Standard In 2013 For The Treatment Of Obesity

Preventing Medical Errors: Warning on Counterfeit Alli

Consumers Alerted to Risks Presented by Counterfeit Alli

Combination Drugs for Treating Obesity

Effect of Non Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia.

Journal Scan: A Randomized Trial of a Low-Carbohydrate Diet vs Orlistat Plus a Low-Fat Diet for Weight Loss (Arch Intern Med 2010;170:136-145.)

A European review of orlistat has concluded that there is insufficient evidence to show that the drug is associated with more serious liver disorders

[Correspondence] Liraglutide for weight loss in obese people

Obesity in adults

Peptides from purified soybean β-conglycinin inhibit fatty acid synthase by interaction with the thioesterase catalytic domain

MHRA: Orlistat safety update

Warning: Counterfeit Alli

Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care

Low-Carb Diet May Lead To Similar Benefits As Weight Loss Medication Combined With A Low-Fat Diet

Low-Carb Diet May Lead To Similar Benefits As Weight Loss Medication Combined With A Low-Fat Diet

Significant Visceral Fat Loss Seen Within 12 Weeks With Orlistat

Low-carb diet better for weight loss and BP reduction than orlistat

Low-carb diet better for weight loss and BP reduction than orlistat

Effectiveness of Weight Management Interventions in Children: A Targeted Systematic Review for the USPSTF

Counterfeit Alli Poses Risks to Consumers, FDA Warns

Liraglutide Fosters Weight Loss in Obese

FDA: Counterfeit Alli Is Hazardous

Fake Alli Has Dangerous Dose of Sibutramine

Counterfeit Alli Has High Doses of Sibutramine

Lipase inhibitor orlistat decreases incorporation of eicosapentaenoic and docosahexaenoic acids in rat tissues

In New Data Alli Proven To Reduce Visceral Fat, A Dangerous Fat Linked To Many Life-Threatening Diseases

In New Data Alli Proven To Reduce Visceral Fat, A Dangerous Fat Linked To Many Life-Threatening Diseases

Low-carb diet beats drug to lower blood pressure

Paper round: Thursday

Low-carb diets and blood pressure

Alli proven to reduce visceral fat, a dangerous fat linked to many life-threatening diseases

MHRA warns of dangers of counterfeit anti-obesity drug alli

MHRA warns public about fake orlistat sold online

Low-Carb Ketogenic Diet Gets Better Results Than Diet Pill

Low Carb Diet Lowered Blood Pressure More Effectively Than Weight Loss Pill

Low Carb Diet Lowered Blood Pressure More Effectively Than Weight Loss Pill

Low-carb diet effective at lowering blood pressure

Low-Carb Diet Effective At Lowering Blood Pressure

Low-Carb Diet Effective At Lowering Blood Pressure

Warning Over Internet Sales Of Counterfeit Weight Loss Medication

Warning Over Internet Sales Of Counterfeit Weight Loss Medication

MHRA warning on internet sales of counterfeit weight loss medication

Low carbohydrate diet similar to orlistat plus low fat diet for weight loss and may reduce BP better

A Randomized Trial of a Low-Carbohydrate Diet vs Orlistat Plus a Low-Fat Diet for Weight Loss [Original Investigation]

Nonsurgical Weight Loss for Extreme Obesity in Primary Care Settings: Results of the Louisiana Obese Subjects Study [Original Investigation]

Low-Carb Diet Edges Low Fat Plus Weight-Loss Drug (CME/CE)

Feds Find Twice Max Dose of Stimulant in Weight Drug Fake

Counterfeit Alli Prompts FDA Warning

Fake Alli diet pills can pose health risks

Alli 60 mg capsules (120 count refill kit): Counterfeit Product

FDA warns of counterfeit AlliT (orlistat) 60 mg capsules (120 count refill kit) sold online

Fake Alli Sold on Internet

FDA Warns About Counterfeit Weight Loss Drug Alli

Drug Safety: OTC Med Recall Expansion, Counterfeit Alli

FDA Warns of Fake OTC Weight-Loss Drug

FDA Warns Consumers about Counterfeit Alli

FDA Warns Consumers About Counterfeit Alli

FDA Warns Consumers About Counterfeit Alli

FDA Warns Consumers about Counterfeit Alli

Fake Alli Sold on Internet

Cochrane review: Long-term effects of weight-reducing drugs in hypertensive patients

FDA Warns of Fake Alli

Alli 60 mg capsules (120 count refill kit): Counterfeit Product

FDA Warns Consumers about Counterfeit Alli

FDA Warns Consumers about Counterfeit Alli

Acute pancreatitis following orlistat therapy: report of two cases.

ALLI (Orlistat) Capsule [GlaxoSmithKline Consumer Healthcare LP]

Transgene in pact with Dr Reddy's for obesity drug

Transgene in pact with Dr Reddy's for obesity drug

Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction

Activity-Based Proteome Profiling of Potential Cellular Targets of Orlistat − An FDA-Approved Drug with Anti-Tumor Activities

Table of Contents

Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis

Cochrane review: Interventions for treating obesity in children

Use of psychotropic drugs and analgesics among users of antiobesity drugs - a population based study

Journal Scan: Effects of Liraglutide in the Treatment of Obesity: A Randomised, Double-Blind, Placebo-Controlled Study (Lancet 2009;374:1606-1616.)